Core Insights - Caris Life Sciences reported a full year revenue growth of approximately 94%, driven by strong performance in molecular profiling services [1][6] - The company completed approximately 199,300 clinical therapy selection cases in 2025, marking a 22% increase from the previous year [6] - Caris aims to establish a new standard in precision medicine through its comprehensive molecular profiling platform and advanced AI technologies [3][7] Financial Performance - For the full year 2025, total revenue reached approximately $800 million, with molecular profiling services contributing about $755 million [6] - The fourth quarter of 2025 saw total revenue of approximately $281 million, an increase of about 116% compared to the same period in 2024 [6] - As of December 31, 2025, the company reported cash, cash equivalents, restricted cash, and marketable securities of approximately $802 million, reflecting a net increase of about $43 million from September 30, 2025 [2] Business Development - The company is focused on expanding clinical adoption and advancing a differentiated pipeline in precision medicine [3] - Caris Life Sciences plans to report complete financial results for the fourth quarter and full year 2025 during its earnings call in late February 2026 [5] - The company has established a large-scale, multimodal clinico-genomic database to enhance its precision medicine diagnostic solutions [7]